LR
Therapeutic Areas
Cognition Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| CT1812 | Mild-to-Moderate Alzheimer's Disease | Phase 2 |
Leadership Team at Cognition Therapeutics
AC
Anthony Caggiano
Chief Medical Officer
KI
Kenneth I. Moch
Chairman of the Board
JM
Jeffrey M. Dayno
Director